Acorda Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Acorda Therapeutics, Inc.
The new continuous glucose sensor is the smallest and thinnest in the world, according to Abbott.
For a biotech launching its first product the pandemic has compounded the usual pressures of a competitive indication against deeper-pocketed competition.
Sun Pharma and Bausch have decided to settle litigation over rifaximin, granting the generics company a non-exclusive license effective 1 January 2028.
Keeping Track: New Nucala Indication; BMS’ Ide-Cel Clears Filing Hurdle; First Applications From Telix And ADC Therapeutics
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
- Drug Delivery
- Other Names / Subsidiaries
- Neuronex, Inc.
- Civitas Therapeutics
- Biotie Therapies Corp.
- Elbion GmbH
- Synosia Therapeutics, Inc.